ASX-listed New Zealand firm Volpara Health is collaborating with Microsoft on a new R&D project looking at using Volpara’s mammogram software to potentially identify cardiovascular issues.

Volpara recently won a patent for its breast arterial calcifications (BACs) technology. BACs are often observed through screening mammography but while they are not thought to be allied to increased breast cancer risk, they may be indicative of arteriosclerosis.